Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT00731380
First received: August 6, 2008
Last updated: July 3, 2014
Last verified: June 2014
  Purpose

The purpose of this study is to determine the highest dose of a ABI-007 that can be given with cisplatin and 5-fluorouracil without causing intolerable side effects in patients with advanced head and neck cancer.


Condition Intervention Phase
Head and Neck Cancer
Drug: ABI-007
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Trial of ABI-007 (Abraxane) Plus Cisplatin Plus 5-Fluorouracil (APF) as Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With Locally Advanced Squamous Cell Cancers of the Head and Neck (HNSCC)

Resource links provided by NLM:


Further study details as provided by University Health Network, Toronto:

Primary Outcome Measures:
  • The maximum tolerated dose of ABI-007 with Cisplatin and 5-Fluorouracil (APF) [ Time Frame: two years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • safety and tolerability profiles for ABI-007 [ Time Frame: two years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 27
Study Start Date: July 2008
Estimated Study Completion Date: March 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: ABI-007
    Dose escalation beginning with ABI-007 75 mg/m2 day 1 + day 8, Cisplatin 100 mg/m2 day 1, 5-FU 1000 mg/m2/d continuous infusion x 96 hours on day 1-4, for 3 weeks x 3 cycles. Followed by Concurrent weekly Carboplatin (AUC 1.5) with radiotherapy for 7 weeks. Carboplatin should be given on Monday or Tuesday of each week, if possible.
    Other Name: Abraxane
Detailed Description:

Squamous cell carcinoma of the head and neck (HNSCC) is the 9th most common malignancy diagnosed in Canadians. In the year 2007, there was an estimated 4,350 new cases diagnosed in Canada, with approximately 1,600 deaths attributable to HNSCC[Canadian Cancer Statistics 2007]. In the United States there is an annual incidence of approximately 40,000 newly diagnosed cases of head and neck cancer [US Cancer Statistics 2006]. Primary treatment for newly diagnosed localized (stage I-II) HNSCC is surgery and/or radiotherapy. The majority of patients (70%) however present with locally advanced HNSCC (Stage III or IV). Treatment of locally advanced HNSCC generally consists of either concurrent chemotherapy and radiation or surgical resection followed by adjuvant radiation or adjuvant concurrent chemotherapy and radiation. Unfortunately despite aggressive treatment with combined modality therapies approximately 40-50% of cases recur, with the majority recurring at the primary site and/or regional nodes. Except for a small minority of patients in whom salvage surgery or radiotherapy can be delivered, the prognosis for the majority of these patients is poor and further treatment is generally considered palliative.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Previously untreated squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Histological or cytological confirmation is required. The disease must be considered to be potentially curable by combined chemoradiation. Patients with nasopharynx, paranasal sinus, skin or unknown primary sites are not eligible.
  2. Non-metastatic, stage III or IV disease (UICC/AJCC classification, 6th edition)
  3. Age ≥ 18.
  4. ECOG performance status of 0 or 1.
  5. Patients must have adequate hematological function:

    • absolute granulocyte count > 1.5 x 109/L
    • platelet count >100 x 109/L
    • hemoglobin > 90 g/L
  6. Must have adequate renal and hepatic function:

    • serum bilirubin < 1.5x UNL and AST/ALT <2.5x UNL
    • serum creatinine < 1.25 x UNL or a calculated creatinine clearance of > 60 ml/min
  7. Signed written consent.
  8. Availability for follow-up for up after treatment.
  9. The patient is fertile and is aware of the risk of becoming pregnant or fathering children and will use adequate contraception (oral contraception, IUD, diaphragm and spermicide or male condom and spermicide) throughout therapy and for at least 3 months after therapy.
  10. Life expectancy greater than 6 months

Exclusion Criteria:

  1. Significant inter-current illness that will interfere with the chemotherapy or radiation therapy during the trial such as HIV infection, cardiac insufficiency, pulmonary compromise, active significant alcohol abuse, uncontrolled psychotic disorder, active infection or febrile illness.
  2. Any history of myocardial infarction, any history of ventricular arrhythmias, angina or active coronary heart disease within 6 months. Significant cardiac disease resulting in an inability to tolerate the intravenous fluid load as required for administration of cisplatin.
  3. Evidence of distant metastases.
  4. Symptomatic peripheral neuropathy ≥ grade 1 by CTCAE v.3 criteria.
  5. Clinically significant sensorineural hearing impairment which may be exacerbated by cisplatin (audiometric abnormalities without corresponding clinical deafness will not be grounds for exclusion)
  6. Weight loss greater than 20% of usual body weight in the 3 months preceding trial entry.
  7. High risk for poor compliance with therapy or follow-up as assessed by investigator.
  8. Pregnant or lactating women.
  9. Prior radiation therapy to greater than 30% of the bone marrow
  10. Prior experimental therapy for cancer within 30 days of entering the trial.
  11. Prior radiation for head and neck cancer.
  12. Prior systemic chemotherapy for cancer.
  13. Patients with prior cancers, except: those diagnosed more than five years ago with no evidence of disease recurrence and a clinical expectation of recurrence of less than 5%; or successfully treated non-melanoma skin cancer; or carcinoma in situ of the cervix. However, any patient with previous invasive breast cancer, prostate cancer or melanoma is excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00731380

Locations
Canada, Ontario
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 3M9
Sponsors and Collaborators
University Health Network, Toronto
Celgene Corporation
Investigators
Principal Investigator: Lillian Siu, MD University Health Network - Princess Margaret Hospital
  More Information

No publications provided by University Health Network, Toronto

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University Health Network, Toronto
ClinicalTrials.gov Identifier: NCT00731380     History of Changes
Other Study ID Numbers: APF-001
Study First Received: August 6, 2008
Last Updated: July 3, 2014
Health Authority: Canada: Health Canada

Keywords provided by University Health Network, Toronto:
Abraxane
Head and Neck Cancer
Determine
Maximum
Tolerated dose
ABI-007
Combination
Cisplatin
5-Fluorouracil
Patients

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms
Neoplasms by Site
Cisplatin
Fluorouracil
Paclitaxel
Antimetabolites
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Tubulin Modulators

ClinicalTrials.gov processed this record on November 20, 2014